Naltrexone/Buproprion

Clare Lee, M.D., MHS, Brian Pinto, Pharm.D.
Naltrexone/Buproprion is a topic covered in the Johns Hopkins Diabetes Guide.

To view the entire topic, please or .

Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:

-- The first section of this topic is shown below --

INDICATIONS

FDA

  • Naltrexone/bupropion was approved as an adjunct to diet and exercise in adults with BMI ≥30 kg/m2 or ≥27 kg/m2 with one or more weight-related comorbidities to achieve weight loss.

-- To view the remaining sections of this topic, please or --

INDICATIONS

FDA

  • Naltrexone/bupropion was approved as an adjunct to diet and exercise in adults with BMI ≥30 kg/m2 or ≥27 kg/m2 with one or more weight-related comorbidities to achieve weight loss.

There's more to see -- the rest of this entry is available only to subscribers.

Last updated: August 22, 2017